Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
| dc.contributor.author | Kudo, M. | |
| dc.contributor.author | Rimassa, L. | |
| dc.contributor.author | Chan, S. L. | |
| dc.contributor.author | Sangro, B. | |
| dc.contributor.author | Lau, G. | |
| dc.contributor.author | Breder, V. V. | |
| dc.contributor.author | Varela Calvo, María | |
| dc.contributor.author | (et al.) | |
| dc.date.accessioned | 2025-04-30T09:18:59Z | |
| dc.date.available | 2025-04-30T09:18:59Z | |
| dc.date.issued | 2024 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.uri | https://hdl.handle.net/10651/78685 | |
| dc.description.sponsorship | AstraZeneca | |
| dc.format.extent | p. S1451-S1452 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Annals of Oncology | |
| dc.rights | ©, | |
| dc.source | WOS:001401985200121 | |
| dc.title | Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) | |
| dc.type | conference output | |
| dc.identifier.doi | 10.1016/j.annonc.2024.10.151 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1016/j.annonc.2024.10.151 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||